{"DataElement":{"publicId":"3781080","version":"1","preferredName":"Acute Myeloid Leukemia Disease Response Status","preferredDefinition":"AML response based on Cheson criteria adapted by Stephen Spurgeon, M.D","longName":"2190138v1.0:3781060v1.0","context":"OHSU Knight","contextVersion":"1","DataElementConcept":{"publicId":"2190138","version":"1","preferredName":"Leukemia Disease Response","preferredDefinition":"information related to leukemia disease response.","longName":"LEUK_DZ_RESP","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206719","version":"1","preferredName":"Leukemia Diseases and Disorders","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C3161:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-01B3-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6E12CB1-3713-3865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-10-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-10-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3781060","version":"1","preferredName":"Acute Myeloid Leukemia Response Status","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003_Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._A condition or state at a particular time.","longName":"3781060v1.0","context":"OHSU Knight","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IA","valueDescription":"Response Unknown Inadequate Assessment","ValueMeaning":{"publicId":"3781061","version":"1","preferredName":"Response Unknown Inadequate Assessment","longName":"3781061","preferredDefinition":"The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.: Not known, not observed, not recorded, or refused.: Not meeting a quantitative or qualitative measure necessary for a requirement.: The final result of a determination of the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Inadequate","conceptCode":"C69177","definition":"Not meeting a quantitative or qualitative measure necessary for a requirement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C0679207","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DAC4-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED838C9-798C-155F-E040-BB89AD43072C","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"ID","valueDescription":"Increase Disease or Disorder","ValueMeaning":{"publicId":"3781062","version":"1","preferredName":"Increase Disease or Disorder","longName":"3781062","preferredDefinition":"Increase; a process of becoming larger or more numerous or more important.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Increase","conceptCode":"C25533","definition":"A process of becoming larger, more numerous, more important, or more likely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DAEA-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DB03-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"SD","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2560100","version":"1","preferredName":"Stable Disease","longName":"2560100","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DB0D-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"PR","valueDescription":"Partial remission","ValueMeaning":{"publicId":"3781063","version":"1","preferredName":"Partial remission","longName":"3781063","preferredDefinition":"Peripheral blood counts: ANC >= 1000/mm^3 (>= 1.0 x 10^9/L). Platelet count >= 100000/mm^3 (>= 100.0 x 10^9/L).  Bone marrow:  Decrease in the pre-treatment blast percentage by at least 50%, and reduction to a value between 5% and 25% of the nucleated cell differential count.  If Auer rods are present, reduction in blast percentage to < 5%.  No extramedullary leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DB17-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DB2F-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"CRc","valueDescription":"AML cytogenic complete remission","ValueMeaning":{"publicId":"3781064","version":"1","preferredName":"AML cytogenic complete remission","longName":"3781064","preferredDefinition":"CR or CRi as defined above with disappearance of previous (pretherapy) cytogenetic abnormalities, i.e., return to normal karyotype, as determined by central hematopathology review","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DB3A-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DB53-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"CRd","valueDescription":"Complete remission with dysplasia","ValueMeaning":{"publicId":"3781065","version":"1","preferredName":"Complete remission with dysplasia","longName":"3781065","preferredDefinition":"CR or CRi as defined above but marrow and/or peripheral blood show persistent dysplasia, as determined by central pathology review","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DB5D-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DB76-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"CR/CRi","valueDescription":"Confirmed complete remission with or without complete hematopoietic recovery","ValueMeaning":{"publicId":"3781066","version":"1","preferredName":"Confirmed complete remission with or without complete hematopoietic recovery","longName":"3781066","preferredDefinition":"Satisfying all criteria for CR or CRi at least 30 days after initial determination of CR.  CRi following remission induction therapy, or immediately prior to post-remission therapy if such therapy occurs within 30 days from the initial determination of CR or CRi","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DB80-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DB99-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"CRi","valueDescription":"Complete remission with incomplete hematopoietic recovery","ValueMeaning":{"publicId":"3781067","version":"1","preferredName":"Complete remission with incomplete hematopoietic recovery","longName":"3781067","preferredDefinition":"Satisying all criteria for CR except for:  ANC < 1000/mm^3 and/or Platelet count < 100000/mm^3 but not reequiring platelet transfusion","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DBA3-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DBBC-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"},{"value":"CR","valueDescription":"Complete remission","ValueMeaning":{"publicId":"3781068","version":"1","preferredName":"Complete remission","longName":"3781068","preferredDefinition":"Peripheral blood counts:  ANC >= 1000/mm^3; Platelet count >=100000/mm^3.  Bone marrow:  No Auer rods; <5% blast cells in a 200-cell differential.  No extramedullary leukemia","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DBC6-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DED78A06-DBDE-8BCD-E040-BB89AD434064","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3781059","version":"1","preferredName":"Acute Myeloid Leukemia Response Status","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003:Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.:A condition or state at a particular time.","longName":"C3171:C25755:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DA99-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"ONEDATA","dateModified":"2013-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DAAA-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"HARTLEYG","dateModified":"2013-07-02","changeDescription":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"AML_DIS_RESP_STATUS","type":"Context Short Name","context":"OHSU Knight"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"2190138v1.0:3781060v1.0","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Best Response AML","type":"Preferred Question Text","description":"Best Response AML","url":null,"context":"OHSU Knight"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Disease Status","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED78A06-DD0B-8BCD-E040-BB89AD434064","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-10","modifiedBy":"FORMBUILDER","dateModified":"2015-09-15","changeDescription":"OHSU 7195 ghd 06.10.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}